Gilead Sciences, Inc. (NASDAQ:GILD) announced the approval of its HIV-1 infection by U.S. Food And Drug Administration.

HIV-1 infection has killed more people around the world than anybody can count. Many companies tried their hands on developing a treatment for this disease, but failed miserably. However, the story is a bit different with Gilead Sciences, Inc. Its newly developed treatment Odefsey (rilpivirine 25 mg/ emtricitabine 200 mg/tenofovir alafenamide 25 mg) has been approved by FDA to be used for certain patients in special cases.

Insights of Matter

As per the reports, tenofovir alafenamide and emtricitabine belong to Gilead Sciences, while rilpivirine has been provided by Janssen Sciences Ireland UC, a wholly owned subsidiary of Janssen Pharmaceutical Companies. Odefsey is the second regimen that has received FDA approval. It is recommended to be used on those patients who are 12 years or older and have never dealt with antiretroviral treatment in the past. Additionally, their HIV-1 RNA level should not be more than 100,000 copies per mL.

Odefsey can be treated as an excellent replacement of stable antiretroviral regimen in those patients whose HIV-1 RNA is not more than 50 copies per mL for at least 24 weeks with no treatment failure cases in the past. The drug comes with a warning written on the product label to ensure it’s used in the right manner.

The senior management team of the company is delighted to receive this approval and hopes that it will prove to be a game-changing treatment in the medical science field. According to John C. Martin, CEO & Chairman, Gilead Sciences, with HIV cases increasing day by day, patients need a treatment that can help them live healthy for a long time. Odefsey is good enough to live up to their expectations.

Going forward, Gilead Sciences will continue to make improvements in the current treatments to make them more feasible, result oriented and effective.